Lumida
/DXCM
⌘K
Dexcom Inc

Dexcom Inc

DXCM
$83.03USD-1.75%-1.48 today

MARKET CAP

31.3B

P/E (TTM)

34.8x

FWD P/E

29.4x

DAY RANGE

$83 – $86

52W RANGE

$54
$93

AI Summary

Stalk
StalkMedium

DXCM is in a Stage 2 corrective phase within an overall uptrend, pulling back into the rising 50-period SMA. Medium-term bias remains bullish as long as the 50 SMA holds. Short-term price is below the 9- and 20-period EMAs, signaling a pause rather than a reversal. Execution should be deferred until a clear bounce or reversal candle off the 50 SMA confirms support. A breakdown below this zone risks a deeper retracement toward the 200-period SMA.

  • Q2 2026 revenue $1.31 B (+13% YoY) driven by global CGM demand
  • Anticipated Medicare coverage for ~12 M type 2 patients expands addressable market
  • Negative earnings yield suggests stock may be overvalued amid competitive pressure
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2021FY 2022FY 2023FY 2024FY 2025TREND
Sales, Adj.$2.4B$2.9B$3.6B$4.0B$4.7B
YoY %+27.1%+18.8%+24.5%+11.3%+15.6%
P / Sales23.5x16.9x14.5x8.0x5.8x
EV / Sales24.3x17.8x15.5x8.9x6.3x
Gross Profit, Adj.$1.7B$1.9B$2.3B$2.4B$2.8B
YoY %+31.3%+12.1%+21.5%+6.5%+14.9%
Margin %68.6%64.7%63.2%60.5%60.1%
EV / Gross Profit35.3x27.4x24.5x14.7x10.6x
EBITDA, Adj.$367.8M$547.1M$783.7M$817.7M$1.2B
YoY %+0.3%+48.7%+43.2%+4.3%+42.3%
Margin %15.0%18.8%21.6%20.3%25.0%
EV / EBITDA161.5x94.4x71.5x43.9x25.4x
EBIT$265.8M$391.2M$597.7M$600.0M$911.8M
YoY %-11.3%+47.2%+52.8%+0.4%+52.0%
Margin %10.9%13.4%16.5%14.9%19.6%
EV / EBIT223.5x132.1x93.7x59.8x32.5x
Net Income$216.9M$341.2M$541.5M$576.2M$836.3M
YoY %-60.5%+57.3%+58.7%+6.4%+45.1%
Net Margin8.9%11.7%14.9%14.3%17.9%
EPS (GAAP)$0.53$0.82$1.30$1.42$2.09
YoY %-60.2%+54.7%+58.5%+9.2%+47.2%